IFN-β1a (recombinant human)

Home
Ligands
IFN-β1a (recombinant human)

GtoPdb Ligand ID: 8339

Synonyms: Avonex® | Rebif®

IFN-β1a (recombinant human) is an approved drug (FDA (1996), EMA (1997))

Compound class: Peptide or derivative

Comment: Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).

No information available.

No information available.

Summary of Clinical Use
IFN-β1a is used clinically to treat relapsing forms of multiple sclerosis [1]. Two brands of recombinant IFN-β1a are available: Avonex® and Rebif®, both of which are produced in Chinese Hamster Ovary cells and are glycosylated peptides.

Summary of Clinical Use

IFN-β1a is used clinically to treat relapsing forms of multiple sclerosis [1]. Two brands of recombinant IFN-β1a are available: Avonex® and Rebif®, both of which are produced in Chinese Hamster Ovary cells and are glycosylated peptides.

Mechanism Of Action and Pharmacodynamic Effects
IFN-β1a activates interferon receptors and induces expression of genes involved in antiviral, immunomodulatory and antiproliferative effects. The mechanism of action underlying the therapeutic benefit of IFN-β1a therapy remains unclear.

Mechanism Of Action and Pharmacodynamic Effects

IFN-β1a activates interferon receptors and induces expression of genes involved in antiviral, immunomodulatory and antiproliferative effects. The mechanism of action underlying the therapeutic benefit of IFN-β1a therapy remains unclear.